412 related articles for article (PubMed ID: 26550915)
1. [Prognostic factors in light chain amyloidosis].
Jávorniczky NR; Bodó I; Masszi T; Mikala G
Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
[TBL] [Abstract][Full Text] [Related]
2. [Heart transplantation in AL amyloidosis].
Dahlberg P; Bartfay SE; Karason K; Mellqvist UH; Bollano E
Lakartidningen; 2018 Mar; 115():. PubMed ID: 29583159
[TBL] [Abstract][Full Text] [Related]
3. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
5. [Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Nagamachi Y; Yamauchi N; Muramatsu H; Miyajima N; Inomata H; Okamoto T; Nozawa E; Gotoh Y; Koyama R; Ihara K; Nishisato T; Kato J
Rinsho Ketsueki; 2015 Mar; 56(3):323-8. PubMed ID: 25876787
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report.
Al-Zoairy R; Viveiros A; Zoller H; Schneeberger S; Oberhuber G; Gunsilius E; Tilg H; Wolf D; Rudzki JD
J Med Case Rep; 2020 Oct; 14(1):201. PubMed ID: 33099313
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Abdallah AA; Alapat D; Kaur V; Atrash S
J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
[TBL] [Abstract][Full Text] [Related]
8. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
9. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
10. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
[TBL] [Abstract][Full Text] [Related]
11. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
[TBL] [Abstract][Full Text] [Related]
12. Primary (AL) amyloidosis in plasma cell disorders.
Müller AM; Geibel A; Neumann HP; Kühnemund A; Schmitt-Gräff A; Böhm J; Engelhardt M
Oncologist; 2006; 11(7):824-30. PubMed ID: 16880241
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Light Chain Deposition Disease Mimicking Immunoglobulin Light Chain Amyloidosis: Two Branches of the Same Tree.
Osanami A; Yano T; Takemura G; Ikeda H; Inyaku M; Toda Y; Kamiyama N; Sugawara H; Gocho Y; Fujito T; Nagano N; Takahashi S; Muranaka A; Tanaka M; Moniwa N; Murase K; Takada K; Kuroda H; Ogawa Y; Miura T
Circ Cardiovasc Imaging; 2020 Sep; 13(9):e010478. PubMed ID: 32873072
[No Abstract] [Full Text] [Related]
15. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma.
Giarin MM; Giaccone L; Sorasio R; Sfiligoi C; Amoroso B; Cavallo F; Cipriani A; Palumbo A; Boccadoro M
Clin Chem; 2009 Aug; 55(8):1510-6. PubMed ID: 19520760
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
[TBL] [Abstract][Full Text] [Related]
17. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
[TBL] [Abstract][Full Text] [Related]
18. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis.
Trachtenberg BH; Kamble RT; Rice L; Araujo-Gutierrez R; Bhimaraj A; Guha A; Park MH; Hussain I; Bruckner BA; Suarez EE; Victor DW; Adrogue HE; Baker KR; Estep JD
Am J Transplant; 2019 Oct; 19(10):2900-2909. PubMed ID: 31152491
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.
Mancio Silva J; Fontes-Carvalho R; Valente D; Almeida C; Cruz AJ; Tente D; Coelho H; Oliveira M; Albuquerque A; Ribeiro VG
Am J Case Rep; 2015 Mar; 16():174-81. PubMed ID: 25803181
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]